8-K 1 h05674e8vk.txt TEXAS BIOTECHNOLOGY CORPORATION SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities and Exchange Act of 1934 Date of Report: (Date of earliest event reported): May 8, 2003 TEXAS BIOTECHNOLOGY CORPORATION (Exact name of registrant as specified in its charter)
DELAWARE 0-20117 13-3532643 (State of Incorporation) (Commission File Number) (IRS Employer Identification No.)
7000 FANNIN, 20TH FLOOR HOUSTON, TEXAS 77030 (Address of Registrant's principal executive offices) (713) 796-8822 (Registrant's telephone number, including area code) (NOT APPLICABLE) (Former name or former address, if changed since last report) ITEM 7. FINANCIAL STATEMENTS, PRO FORMA FINANCIAL INFORMATION AND EXHIBITS (a) Financial Statements of Business Acquired None. (b) Pro Forma Financial Information. None. (c) Exhibits. 99.1 Press release issued by Texas Biotechnology Corporation dated May 8, 2003 ITEM 9. REGULATION FD DISCLOSURE In accordance with Securities and Exchange Commission Release Nos. 33-8216 and 34-47583, the following information, which is intended to be furnished under Item 12, "Results of Operations and Financial Condition," is instead being furnished under Item 9, "Regulation FD Disclosure." The information in this Current Report is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 (the "Exchange Act"), or otherwise subject to the liabilities of that Section. The information in this Current Report shall not be incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing. On May 8, 2003, Texas Biotechnology Corporation ("TBC") issued a press release regarding TBC's financial results for its first fiscal quarter ended March 31, 2003. The full text of TBC's press release is furnished herewith as Exhibit 99.1. [SIGNATURE PAGE FOLLOWS] SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. Date May 8, 2003 TEXAS BIOTECHNOLOGY CORPORATION /s/ Stephen L. Mueller ------------------------------------------ Stephen L. Mueller Vice-President, Finance and Administration Secretary and Treasurer EXHIBIT INDEX Exhibit No. Description ----------- ----------- 99.1 Press release issued by Texas Biotechnology Corporation dated May 8, 2003